Intriguingly, a large-scale study of type 2 diabetes patients found that the use of glucagon-like peptide-1 (GLP-1) receptor agonists and inhibitors of the GLP-1 degrading enzyme dipeptidyl peptidase 4 (DPP-4) significantly reduced the incidence of PD. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.